Document is current
Any future updates will be listed below
-
Authors
Chauhan, A. J.
Eriksson, G.
Storrar, W.
Brown, T.
Peterson, S.
Radner, F.
D’Cruz, L. G.
Miller, P.
Bjermer, L.
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 9 August 2022
Accepted: 25 October 2022
First Online: 9 November 2022
Declarations
:
: All experimental protocols were approved by Health Research Authority: NRES Committee South Central – Berkshire REC Reference 14/SC/0092, IRAS Project ID 148386. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian(s). For further details see LASER HTA report [].
: Not applicable.
: AJC was Chief Investigator of the LASER Trial (and responsible for the post hoc analysis) and currently conducting the LASER-48 trial funded by Airsonett. He has been on the advisory board for Sanofi Genzyme, Novartis, XIM and Exhalation Technology. GE has been on advisory boards for Airsonett, Almirall and AstraZeneca and has consulted for Airsonett and other pharma companies. WS was the principal investigator on the LASER trial. TB has been on the advisory board for Astra Zeneca and was also a co-applicant on the grant for the LASER trial. SP and PM have consulted for Airsonett and other pharma companies. LGD and FR have no conflicts of interest to report. LBJ was on the scientific advisory board and an investigator on the 4A trial. In addition, he has given paid lectures during Airsonett symposia at international conferences.
